The Experts below are selected from a list of 43923 Experts worldwide ranked by ideXlab platform
Richard L. Wahl - One of the best experts on this subject based on the ideXlab platform.
-
reply radiation dose does matter mechanistic insights into dna damage and repair support the linear no threshold model of low dose radiation health risks
The Journal of Nuclear Medicine, 2018Co-Authors: James R Duncan, Michael R Lieber, Noritaka Adachi, Richard L. WahlAbstract:1014 Objectives: Human internal Dosimetry of new radiopharmaceuticals should have presumed by the animal data. Cu-64 labeled radiopharmaceuticals has possibly can use PET imaging and therapeutic effect assuming of convergence radiopharmaceutical. The aim of this study has evaluated the Cu-64 labeled radiopharmaceutical projected human internal Dosimetry using small animal biodistribution and image data. Methods: Cu-64 labeled radiopharmaceutical PET image was acquired using small animal PET/CT system (Inveon, Siemens Healthcare.) in mouse (n = 3) at 1, 2, 6, 24, 48 and 72 hour after intravenous injection of Cu-64 labeled radiopharmaceutical. Each organ region was defined by contrast mouse CT image (Exitron nano 12000, Miltenyi Biotec). In this study, three internal Dosimetry method which are animal derived, human extrapolated, and object specific Dosimetry. Animal derived Dosimetry method was estimated by estimated biodistribution in mouse and human S-value. Human extrapolate Dosimetry method was calculated extrapolated human biodistribution and human S-value. Object specific Dosimetry method was calculated using image based residence time and object specific S-value. Object specific S-value was calculated based on individual small animal CT image using Monte Carlo simulation. Results: Animal derived absorbed dose in heart, lung, liver, spleen were 0.048 ± 0.006, 0.028 ± 0.012, 0.079 ± 0.002, 0.047 ± 0.005 mGy/MBq, respectively. Human extrapolated absorbed dose were 0.054 ± 0.007 for heart, 0.102 ± 0.017 for lung, 0.118 ± 0.012 for liver, and 0.100 ± 0.013 mGy/MBq for spleen. Object specific absorbed dose were 0.053 ± 0.006 for heart, 0.027 ± 0.005 for lung, 0.035 ± 0.005 for liver, 0.025 ± 0.003 mGy/MBq for spleen. According to the absorbed dose, extrapolate Dosimetry method has more higher estimated Cu-64 absorbed dose in lung, liver, spleen region than animal derived and object specific Dosimetry Methods: Conclusion: We evaluated the human projected internal Dosimetry using Cu-64 small animal data. Human extrapolated dose was overestimated in lung, liver, and spleen. Object specific Dosimetry will be applied for diagnostic and therapeutic human dose calculation.
-
radiation dose does matter mechanistic insights into dna damage and repair support the linear no threshold model of low dose radiation health risks
The Journal of Nuclear Medicine, 2018Co-Authors: James R Duncan, Michael R Lieber, Noritaka Adachi, Richard L. WahlAbstract:1014 Objectives: Human internal Dosimetry of new radiopharmaceuticals should have presumed by the animal data. Cu-64 labeled radiopharmaceuticals has possibly can use PET imaging and therapeutic effect assuming of convergence radiopharmaceutical. The aim of this study has evaluated the Cu-64 labeled radiopharmaceutical projected human internal Dosimetry using small animal biodistribution and image data. Methods: Cu-64 labeled radiopharmaceutical PET image was acquired using small animal PET/CT system (Inveon, Siemens Healthcare.) in mouse (n = 3) at 1, 2, 6, 24, 48 and 72 hour after intravenous injection of Cu-64 labeled radiopharmaceutical. Each organ region was defined by contrast mouse CT image (Exitron nano 12000, Miltenyi Biotec). In this study, three internal Dosimetry method which are animal derived, human extrapolated, and object specific Dosimetry. Animal derived Dosimetry method was estimated by estimated biodistribution in mouse and human S-value. Human extrapolate Dosimetry method was calculated extrapolated human biodistribution and human S-value. Object specific Dosimetry method was calculated using image based residence time and object specific S-value. Object specific S-value was calculated based on individual small animal CT image using Monte Carlo simulation. Results: Animal derived absorbed dose in heart, lung, liver, spleen were 0.048 ± 0.006, 0.028 ± 0.012, 0.079 ± 0.002, 0.047 ± 0.005 mGy/MBq, respectively. Human extrapolated absorbed dose were 0.054 ± 0.007 for heart, 0.102 ± 0.017 for lung, 0.118 ± 0.012 for liver, and 0.100 ± 0.013 mGy/MBq for spleen. Object specific absorbed dose were 0.053 ± 0.006 for heart, 0.027 ± 0.005 for lung, 0.035 ± 0.005 for liver, 0.025 ± 0.003 mGy/MBq for spleen. According to the absorbed dose, extrapolate Dosimetry method has more higher estimated Cu-64 absorbed dose in lung, liver, spleen region than animal derived and object specific Dosimetry Methods: Conclusion: We evaluated the human projected internal Dosimetry using Cu-64 small animal data. Human extrapolated dose was overestimated in lung, liver, and spleen. Object specific Dosimetry will be applied for diagnostic and therapeutic human dose calculation.
M A Bernal - One of the best experts on this subject based on the ideXlab platform.
-
a feasibility study of fricke Dosimetry as an absorbed dose to water standard for 192ir hdr sources
PLOS ONE, 2014Co-Authors: Camila Salata, Mariano Gazineu David, C E Dealmeida, Ricardo Ochoa, Marilene Coelho De Lima, Evandro J Pires, Jose Guilherme Peixoto, M A BernalAbstract:High dose rate brachytherapy (HDR) using 192Ir sources is well accepted as an important treatment option and thus requires an accurate Dosimetry standard. However, a Dosimetry standard for the direct measurement of the absolute dose to water for this particular source type is currently not available. An improved standard for the absorbed dose to water based on Fricke Dosimetry of HDR 192Ir brachytherapy sources is presented in this study. The main goal of this paper is to demonstrate the potential usefulness of the Fricke Dosimetry technique for the standardization of the quantity absorbed dose to water for 192Ir sources. A molded, double-walled, spherical vessel for water containing the Fricke solution was constructed based on the Fricke system. The authors measured the absorbed dose to water and compared it with the doses calculated using the AAPM TG-43 report. The overall combined uncertainty associated with the measurements using Fricke Dosimetry was 1.4% for k = 1, which is better than the uncertainties reported in previous studies. These results are promising; hence, the use of Fricke Dosimetry to measure the absorbed dose to water as a standard for HDR 192Ir may be possible in the future.
Glenn D Flux - One of the best experts on this subject based on the ideXlab platform.
-
eanm Dosimetry committee series on standard operational procedures for internal Dosimetry for 131 i mibg treatment of neuroendocrine tumours
EJNMMI Physics, 2020Co-Authors: Jonathan Gear, Michael Lassmann, Carlo Chiesa, Pablo Minguez Gabina, Johannes Trangia, Caroline Stokke, Glenn D FluxAbstract:The purpose of the EANM Dosimetry Committee Series on “Standard Operational Procedures for Dosimetry” (SOP) is to provide advice to scientists and clinicians on how to perform patient-specific absorbed dose assessments. This SOP describes image and data acquisition parameters and Dosimetry calculations to determine the absorbed doses delivered to whole-body, tumour and normal organs following a therapeutic administration of 131I mIBG for the treatment of neuroblastoma or adult neuroendocrine tumours. Recommendations are based on evidence in recent literature where available and on expert opinion within the community. This SOP is intended to promote standardisation of practice within the community and as such is based on the facilities and expertise that should be available to any centre able to perform specialised treatments with radiopharmaceuticals and patient-specific Dosimetry. A clinical example is given to demonstrate the application of the absorbed dose calculations.
-
eanm Dosimetry committee guidance document good practice of clinical Dosimetry reporting
European Journal of Nuclear Medicine and Molecular Imaging, 2011Co-Authors: Michael Lassmann, Glenn D Flux, C Chiesa, Manuel BardiesAbstract:Many recent publications in nuclear medicine contain data on dosimetric findings for existing and new diagnostic and therapeutic agents. In many of these articles, however, a description of the methodology applied for Dosimetry is lacking or important details are omitted. The intention of the EANM Dosimetry Committee is to guide the reader through a series of suggestions for reporting dosimetric approaches. The authors are aware of the large amount of data required to report the way a given clinical Dosimetry procedure was implemented. Another aim of this guidance document is to provide comprehensive information for preparing and submitting publications and reports containing data on internal Dosimetry. This guidance document also contains a checklist which could be useful for reviewers of manuscripts submitted to scientific journals or for grant applications. In addition, this document could be used to decide which data are useful for a documentation of Dosimetry results in individual patient records. This may be of importance when the approval of a new radiopharmaceutical by official bodies such as EMA or FDA is envisaged.
-
rmdp a dedicated package for 131i spect quantification registration and patient specific Dosimetry
Cancer Biotherapy and Radiopharmaceuticals, 2003Co-Authors: M J Guy, Glenn D Flux, Periklis Papavasileiou, M A Flower, R J OttAbstract:The limitations of traditional targeted radionuclide therapy (TRT) Dosimetry can be overcome by using voxel-based techniques. All Dosimetry techniques are reliant on a sequence of quantitative emission and transmission data. The use of 131I, for example, with NaI or mIBG, presents additional quantification challenges beyond those encountered in low-energy NM diagnostic imaging, including dead-time correction and additional photon scatter and penetration in the camera head. The Royal Marsden Dosimetry Package (RMDP) offers a complete package for the accurate processing and analysis of raw emission and transmission patient data. Quantitative SPECT reconstruction is possible using either FBP or OS-EM algorithms. Manual, marker- or voxel-based registration can be used to register images from different modalities and the sequence of SPECT studies required for 3-D Dosimetry calculations. The 3-D patient-specific Dosimetry routines, using either a beta-kernel or voxel S-factor, are included. Phase-fitting each v...
James R Duncan - One of the best experts on this subject based on the ideXlab platform.
-
reply radiation dose does matter mechanistic insights into dna damage and repair support the linear no threshold model of low dose radiation health risks
The Journal of Nuclear Medicine, 2018Co-Authors: James R Duncan, Michael R Lieber, Noritaka Adachi, Richard L. WahlAbstract:1014 Objectives: Human internal Dosimetry of new radiopharmaceuticals should have presumed by the animal data. Cu-64 labeled radiopharmaceuticals has possibly can use PET imaging and therapeutic effect assuming of convergence radiopharmaceutical. The aim of this study has evaluated the Cu-64 labeled radiopharmaceutical projected human internal Dosimetry using small animal biodistribution and image data. Methods: Cu-64 labeled radiopharmaceutical PET image was acquired using small animal PET/CT system (Inveon, Siemens Healthcare.) in mouse (n = 3) at 1, 2, 6, 24, 48 and 72 hour after intravenous injection of Cu-64 labeled radiopharmaceutical. Each organ region was defined by contrast mouse CT image (Exitron nano 12000, Miltenyi Biotec). In this study, three internal Dosimetry method which are animal derived, human extrapolated, and object specific Dosimetry. Animal derived Dosimetry method was estimated by estimated biodistribution in mouse and human S-value. Human extrapolate Dosimetry method was calculated extrapolated human biodistribution and human S-value. Object specific Dosimetry method was calculated using image based residence time and object specific S-value. Object specific S-value was calculated based on individual small animal CT image using Monte Carlo simulation. Results: Animal derived absorbed dose in heart, lung, liver, spleen were 0.048 ± 0.006, 0.028 ± 0.012, 0.079 ± 0.002, 0.047 ± 0.005 mGy/MBq, respectively. Human extrapolated absorbed dose were 0.054 ± 0.007 for heart, 0.102 ± 0.017 for lung, 0.118 ± 0.012 for liver, and 0.100 ± 0.013 mGy/MBq for spleen. Object specific absorbed dose were 0.053 ± 0.006 for heart, 0.027 ± 0.005 for lung, 0.035 ± 0.005 for liver, 0.025 ± 0.003 mGy/MBq for spleen. According to the absorbed dose, extrapolate Dosimetry method has more higher estimated Cu-64 absorbed dose in lung, liver, spleen region than animal derived and object specific Dosimetry Methods: Conclusion: We evaluated the human projected internal Dosimetry using Cu-64 small animal data. Human extrapolated dose was overestimated in lung, liver, and spleen. Object specific Dosimetry will be applied for diagnostic and therapeutic human dose calculation.
-
radiation dose does matter mechanistic insights into dna damage and repair support the linear no threshold model of low dose radiation health risks
The Journal of Nuclear Medicine, 2018Co-Authors: James R Duncan, Michael R Lieber, Noritaka Adachi, Richard L. WahlAbstract:1014 Objectives: Human internal Dosimetry of new radiopharmaceuticals should have presumed by the animal data. Cu-64 labeled radiopharmaceuticals has possibly can use PET imaging and therapeutic effect assuming of convergence radiopharmaceutical. The aim of this study has evaluated the Cu-64 labeled radiopharmaceutical projected human internal Dosimetry using small animal biodistribution and image data. Methods: Cu-64 labeled radiopharmaceutical PET image was acquired using small animal PET/CT system (Inveon, Siemens Healthcare.) in mouse (n = 3) at 1, 2, 6, 24, 48 and 72 hour after intravenous injection of Cu-64 labeled radiopharmaceutical. Each organ region was defined by contrast mouse CT image (Exitron nano 12000, Miltenyi Biotec). In this study, three internal Dosimetry method which are animal derived, human extrapolated, and object specific Dosimetry. Animal derived Dosimetry method was estimated by estimated biodistribution in mouse and human S-value. Human extrapolate Dosimetry method was calculated extrapolated human biodistribution and human S-value. Object specific Dosimetry method was calculated using image based residence time and object specific S-value. Object specific S-value was calculated based on individual small animal CT image using Monte Carlo simulation. Results: Animal derived absorbed dose in heart, lung, liver, spleen were 0.048 ± 0.006, 0.028 ± 0.012, 0.079 ± 0.002, 0.047 ± 0.005 mGy/MBq, respectively. Human extrapolated absorbed dose were 0.054 ± 0.007 for heart, 0.102 ± 0.017 for lung, 0.118 ± 0.012 for liver, and 0.100 ± 0.013 mGy/MBq for spleen. Object specific absorbed dose were 0.053 ± 0.006 for heart, 0.027 ± 0.005 for lung, 0.035 ± 0.005 for liver, 0.025 ± 0.003 mGy/MBq for spleen. According to the absorbed dose, extrapolate Dosimetry method has more higher estimated Cu-64 absorbed dose in lung, liver, spleen region than animal derived and object specific Dosimetry Methods: Conclusion: We evaluated the human projected internal Dosimetry using Cu-64 small animal data. Human extrapolated dose was overestimated in lung, liver, and spleen. Object specific Dosimetry will be applied for diagnostic and therapeutic human dose calculation.
Michael Lassmann - One of the best experts on this subject based on the ideXlab platform.
-
eanm Dosimetry committee series on standard operational procedures for internal Dosimetry for 131 i mibg treatment of neuroendocrine tumours
EJNMMI Physics, 2020Co-Authors: Jonathan Gear, Michael Lassmann, Carlo Chiesa, Pablo Minguez Gabina, Johannes Trangia, Caroline Stokke, Glenn D FluxAbstract:The purpose of the EANM Dosimetry Committee Series on “Standard Operational Procedures for Dosimetry” (SOP) is to provide advice to scientists and clinicians on how to perform patient-specific absorbed dose assessments. This SOP describes image and data acquisition parameters and Dosimetry calculations to determine the absorbed doses delivered to whole-body, tumour and normal organs following a therapeutic administration of 131I mIBG for the treatment of neuroblastoma or adult neuroendocrine tumours. Recommendations are based on evidence in recent literature where available and on expert opinion within the community. This SOP is intended to promote standardisation of practice within the community and as such is based on the facilities and expertise that should be available to any centre able to perform specialised treatments with radiopharmaceuticals and patient-specific Dosimetry. A clinical example is given to demonstrate the application of the absorbed dose calculations.
-
eanm Dosimetry committee guidance document good practice of clinical Dosimetry reporting
European Journal of Nuclear Medicine and Molecular Imaging, 2011Co-Authors: Michael Lassmann, Glenn D Flux, C Chiesa, Manuel BardiesAbstract:Many recent publications in nuclear medicine contain data on dosimetric findings for existing and new diagnostic and therapeutic agents. In many of these articles, however, a description of the methodology applied for Dosimetry is lacking or important details are omitted. The intention of the EANM Dosimetry Committee is to guide the reader through a series of suggestions for reporting dosimetric approaches. The authors are aware of the large amount of data required to report the way a given clinical Dosimetry procedure was implemented. Another aim of this guidance document is to provide comprehensive information for preparing and submitting publications and reports containing data on internal Dosimetry. This guidance document also contains a checklist which could be useful for reviewers of manuscripts submitted to scientific journals or for grant applications. In addition, this document could be used to decide which data are useful for a documentation of Dosimetry results in individual patient records. This may be of importance when the approval of a new radiopharmaceutical by official bodies such as EMA or FDA is envisaged.
